Castrate Resistant Prostate Cancer Clinical Trials in Boston, Massachusetts
3 recruitingBoston, Massachusetts
Showing 1–3 of 3 trials
Recruiting
Phase 1Phase 2
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals188 enrolled29 locationsNCT07206056
Recruiting
Phase 1Phase 2
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Breast CancerOvarian CancerEndometrial Cancer+8 more
858 Therapeutics, Inc.120 enrolled14 locationsNCT06395519
Recruiting
Phase 1
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Castrate Resistant Prostate CancerNUT CarcinomaChronic Myelomonocytic Leukemia+1 more
Epigenetix, Inc.75 enrolled6 locationsNCT05488548